Albany, NY -- (SBWIRE) -- 04/25/2018 -- Dementia is not a particular disease. The term dementia is generally used for a variety of symptoms related with the decline in thinking ability in connection with severe issues in people’s memory. In most patients, memory issues are so serious that the patient suffering is unable to perform day-to-day regular activities. Generally, dementia is the normal part of ageing. Alzheimer’s is the highly common form of dementia, a simple term used for the loss of cognitive abilities in combination with memory loss, severe enough to obstruct regular activities in daily life. Research findings suggests that Alzheimer’s disease accounts for 50% to 70% of all dementia diseases. For example, vascular dementia, which occurs after a stroke, is the most second most common type of dementia. However, there are several other disorders which can exhibit symptoms similar to dementia. Some of these symptoms are reversible; for instance, vitamin scarcities and thyroid problems etc.

The global Dementia Associated With Alzheimer’s Disease Market is anticipated to expand rapidly in the near future. Globally, approximately 44 million people are suffering from Alzheimer’s or a related dementia, and amongst them only 1 in 4 cases have been diagnosed. According to the Alzheimer’s Association research findings, for the year 2016, in the U.S., the approximate cost of caring for Alzheimer’s patients is projected to be nearly $ 236 billion. For example, 1 out of 9 U.S. citizens, who are aged above 65, has Alzheimer’s disease. These are some factors that are estimated to drive the global dementia associated with Alzheimer’s disease market.

Additionally, a worldwide search is under way to find new and innovative treatments to slow, stop, or even prevent dementia associated with Alzheimer’s disease. Some drugs seem very promising at the early phases of drug development, as the new drugs generally take years to get developed from concept to market; however, they are likely to not work as conceptualized in large-scale clinical trials. Therefore, it is highly important that dementia and related dementia research continues to accelerate. Pharma and biotech companies and researchers at other academic research institutes are looking for new innovative treatment strategies and need more support in terms of funding for research. Conversely, high treatment cost and side effects of the treatment are some factors that are likely to hamper the global dementia associated with Alzheimer’s disease market.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39203



Currently, there is no precise cure for dementia associated with Alzheimer’s disease. The U.S. Food and Drug Administration (FDA) has permitted five prescription drugs to treat its indications. Of the five, three, galantamine, rivastigmine and donepezil, work on the mechanism of ’cholinesterase inhibitors’. These drugs prevent the collapse of chemical messenger in the brain, which is highly important for memory and learning.

Based on region, the global dementia associated with Alzheimer’s disease market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is estimated to expand rapidly in the near future. Some reasons for the domination of this market are well-developed healthcare system, proper reimbursement scenario, and acceptance of the newly advanced techniques. Europe and Asia Pacific follow North America, in terms of share of the global market. Existence of key players and increase in investments in R&D activities by top players, and alliance of the key players with research institutes are key reasons that are driving the global dementia associated with Alzheimer’s disease market.

Key players operating in the global dementia associated with Alzheimer’s disease market include H Lundbeck A/S, Ono Pharmaceutical, Johnson & Johnson, Eisai Co Ltd., and Daiichi Sankyo Company Limited.

Enquiry for discount on this report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39203